# Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects

> **NCT03932916** · PHASE1 · COMPLETED · sponsor: **Shanghai Synergy Pharmaceutical Sciences Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- AD

## Interventions

- **DRUG:** Donepezil Pamoate for Injection 17mg
- **DRUG:** Donepezil Pamoate for Injection 34mg
- **DRUG:** Donepezil Hydrochloride 5mg

## Key facts

- **NCT ID:** NCT03932916
- **Lead sponsor:** Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-02
- **Primary completion:** 2020-08-06
- **Final completion:** 2020-09-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03932916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03932916, "Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03932916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*